Idera is also talking to potential partners | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1485 of 1599  at  1/11/2019 8:13:23 PM  by

fairvalueforyou


 In response to msg 1484 by  liuyiiv
view thread

Re: Idera is also talking to potential partners

I hope that improved data in half year from 2mg cohort(25 patients) in head and neck, and 2mg cohort(25 patients) in  melanoma refractory or resistant to anti-PD-1 could finally  push the partnership deal through...
 
 Idera is desperately for any partnership to survive, it is going to run out the money in a year...
 
 =============================================================
 

In another trial, we reported 27.3% ORR in 22 patients with head and neck cancer who were naïve to anti-PD-1 and received the eight-milligram dose. The activity we've seen in this group was encouraging because the second-line or later patients that we enrolled in this study do progress very rapidly, often before we can even treat. And the response rate that we observed was roughly double that reported from monotherapy. We have now completed enrollment of 25 patients in the two-milligram cohort in this study.

Finally, in melanoma patients refractory or resistant to anti-PD-1, who received the eight-milligram dose, we reported a 20.7% ORR in 29 patients; again, indicating SD-101 is providing benefit significantly beyond monotherapy in this population. We are now completing enrollment of 25 patients at two milligrams in this study. In all three studies, adverse events related to SD-101 treatment were transient mild to moderate flu-like symptoms.

More recently, we reported biomarker data analysis from clinical trials of SD-101 in 3 tumor types. We demonstrated consistent target engagement; induction of type 1 interferon response in the tumor microenvironment; increases in recruitment of key cell types responsible for tumor control; responses regardless of baseline PD-L1 status; and importantly, that the trends in immune infiltrate changes between the two-milligram and eight-milligram groups were entirely consistent with the higher response rates in the two-milligram group.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 145
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1487 Re: Idera is also talking to potential partners snowballsbbmj 0 1/12/2019 1:20:32 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...